These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 39114362)

  • 1. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.
    Zeng Z; Lin H; Jiang M; Yuan J; Li X; Jia Y; Yang L; Zhang H
    Front Pharmacol; 2024; 15():1424606. PubMed ID: 39114362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.
    Petric Z; Goncalves J; Paixao P
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
    D'Amico F; Peyrin-Biroulet L; Danese S
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892780
    [No Abstract]   [Full Text] [Related]  

  • 8. Biosimilars in IBD: What Every Clinician Needs to Know.
    Angyal A; Bhat S
    Curr Gastroenterol Rep; 2024 Mar; 26(3):77-85. PubMed ID: 38243154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.
    Huynh L; Hass S; Peyrin-Biroulet L; Duh MS; Sipsma H; Cheng M; Lax A; Nag A
    Crohns Colitis 360; 2022 Jan; 4(1):otac001. PubMed ID: 36777550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P; Sunkara T; Raj JP
    J Inflamm Res; 2018; 11():215-226. PubMed ID: 29844695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices.
    Bhat S; Qazi T
    Crohns Colitis 360; 2021 Jan; 3(1):otaa093. PubMed ID: 36777069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Bhat S; Limdi JK; Cross RK; Farraye FA
    Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI; Lichtenstein GR
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.